Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

Hazem Elkady

h-index 30 View on Semantic Scholar

We have 6 of 116 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jan 2026

Beyond the Cell: Stem Cell‐Derived Exosomes as Next‐Generation Tools in Regenerative Therapy

Exosomes derived from stem cells have gained significant interest in recent years due to their considerable promise as a cell‐free therapy in drug delivery and regenerative medicine. Their therapeutic appeal lies in their immune‐modulating properties, along with a lower risk of immune response or tumor formation compar...

Hazem Elkady, Majdeldin E. Abdelgilil, Hagar W. Mandour et al. · 0 citations
Sep 2026

Integrated in vitro and in silico evaluations of novel benzanilide derivatives as anticancer agents.

AIMS This study aimed to design, synthesize, and evaluate novel benzanilide derivatives as potential anticancer agents targeting VEGFR-2-mediated tumor angiogenesis. MATERIALS AND METHODS Eight benzanilide derivatives (7a-e, 9a-b, and 11) were synthesized and structurally confirmed using spectroscopic methods. The co...

A. Metwaly, Hazem Elkady, Walid E. Elgammal et al. · 0 citations
Open access Aug 2026

Coumarin-based dual kinase inhibitors targeting CDK6 and VEGFR-2: experimental and computational validation

Mechanistic studies revealed that compound 7e induced significant apoptosis, promoted S-phase cell cycle arrest, and effectively inhibited cell migration in HCT-116 cells, identifying him as a promising dual VEGFR-2/CDK6 inhibitor with potent and selective anticancer activity.

Hazem Elkady, Walid E. Elgammal, I. Eissa et al. · 0 citations
Aug 2026

Integrated In Silico and In Vitro Discovery of a VEGFR-2-Targeted Anticancer Benzanilide Lead

This integrated study pinpointed ACEB-Cl as a promising VEGFR-2targeted anticancer lead compound with strong inhibitory potency, and a clearly defined mechanism of action, supporting its progression for further improvement.

A. Metwaly, I. Eissa, Walid E. Elgammal et al. · 0 citations
Open access Aug 2026

Integrated design, synthesis, biological evaluation, and computational mechanistic insights of novel benzanilide derivatives as VEGFR-2 targeted anticancer agents

Findings identify compound 7e as a promising VEGFR-2-targeted anticancer lead with strong enzymatic inhibition, potent cytotoxicity, and a well-supported mechanistic profile integrating experimental and computational evidence.

A. Metwaly, Walid E. Elgammal, I. Eissa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.